{"id":"NCT01664598","sponsor":"Hoffmann-La Roche","briefTitle":"An Extension Study of WA19926 of the Long-Term Safety of Tocilizumab (RoActemra/Actemra) in Patients With Early Moderate to Severe Rheumatoid Arthritis","officialTitle":"A Multicenter, Open-label, Single Arm, Long Term Extension Study of WA19926 to Describe Safety During Treatment With Tocilizumab in Patients With Early, Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-05","primaryCompletion":"2015-06","completion":"2015-06","firstPosted":"2012-08-14","resultsPosted":"2023-12-11","lastUpdate":"2023-12-11"},"enrollment":49,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Tocilizumab","otherNames":["RoActemra","Actemra"]}],"arms":[{"label":"Tocilizumab","type":"EXPERIMENTAL"}],"summary":"This open-label, single arm, multicenter long-term extension study of WA19926 evaluated the safety and efficacy of tocilizumab (RoActemra/Actemra) in participants with moderate to severe rheumatoid arthritis who completed the 104-week WA19926 core study. Eligible patients received tocilizumab 8 mg/kg intravenously every 4 weeks for up to 104 weeks.","primaryOutcome":{"measure":"Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs of Special Interest (AESIs)","timeFrame":"Up to 112 weeks","effectByArm":[{"arm":"Tocilizumab","deltaMin":69.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":12},"locations":{"siteCount":12,"countries":["Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":49},"commonTop":["Upper respiratory tract infection","Alanine aminotransferase increased","Bronchitis","Aspartate aminotransferase increased","Dyslipidaemia"]}}